Long-term effect of tocilizumab on left ventricular hypertrophy and systolic dysfunction in AA amyloidosis with rheumatoid arthritis

This publication has 10 references indexed in Scilit:

• 18F-florbetaben positron emission tomography detects cardiac involvement in systemic AA amyloidosis
  European Journal of Nuclear Medicine and Molecular Imaging, 2020
• First Nationwide Survey of 199 Patients with Amyloid A Amyloidosis in Japan
  Internal Medicine, 2018
• AA amyloidosis – Benefits and prospects of IL-6 inhibitors
  Modern Rheumatology, 2018
• AA amyloidosis treated with tocilizumab: case series and updated literature review
  Amyloid, 2014
• Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases
  Modern Rheumatology, 2013
• Natural History and Outcome in Systemic AA Amyloidosis
  New England Journal of Medicine, 2007
• Eprodisate for the Treatment of Renal Disease in AA Amyloidosis
  New England Journal of Medicine, 2007
• Recent Advances in Immunopathophysiology of Interleukin-6: An Innovative Therapeutic Drug, Tocilizumab (Recombinant Humanized Anti-human Interleukin-6 Receptor Antibody), Unveils The Mysterious Etiology of Immune-Mediated Inflammatory Diseases
  Biological and Pharmaceutical Bulletin, 2007
• Prevalence of secondary amyloidosis in Asian North Indian patients with rheumatoid arthritis.
  2003
• The clinical significance of amyloid fat deposits in rheumatoid arthritis: A systematic long-term followup study using abdominal fat aspiration
  Arthritis & Rheumatism, 2001